Sunshine Biopharma Authorizes Up to 1-for-20 Reverse Stock Split

What Happened Sunshine Biopharma Inc. (SBFM) filed an 8-K reporting that on September 15, 2026 Dr. Steve N. Slilaty, who holds approximately 97% of the company’s voting power and is the CEO, gave written consent authorizing the board of directors to implement a reverse split of the company’s common stock in a ratio of up to 1-for-20. The board has discretion whether to effect the reverse split and to choose the exact whole-number ratio up to 1-for-20. The shareholder consent will become effective 20 days after the definitive information statement related to the consent is mailed to stockholders.

Key Details

• Consent date: September 15, 2026; Form 8-K filed September 16, 2026.
• Maximum reverse split ratio authorized: up to 1-for-20 (board may choose a whole-number ratio up to that).
• Effective timing: consent becomes effective 20 days after mailing of the definitive information statement.
• Voting control: Dr. Steve N. Slilaty holds ~97% of total voting power and approved the action by written consent.

Why It Matters A reverse stock split, if implemented, would reduce the number of outstanding shares and proportionally increase the per-share price. The board’s discretion on whether and when to effect the split — and at what exact ratio up to 1-for-20 — means investors should watch for a subsequent announcement and the mailing of the definitive information statement for timing and final terms. Because a single stockholder (the CEO) controls most voting power, that holder’s approval effectively enables the board to act without a broader shareholder vote.